SIGA Advances ST-246 Smallpox Antiviral Development In Europe
SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced that its subsidiary, SIGA Pharmaceuticals (Europe) Limited, has qualified as a ’small and medium-sized enterprise’ (SME) with respect to its application for approval of ST-246 in Europe. ST-246 is a smallpox antiviral and SIGA’s lead product candidate.
More: continued here
Filed under: Infectious Diseases / Bacteria / Viruses on April 17th, 2008